WMH

Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024

Retrieved on: 
Monday, March 4, 2024

SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024).

Key Points: 
  • At this conference, Neurophet will introduce Alzheimer's disease treatment related technologies planned to be commercialized such as analysis of the side effect and amyloid-positive prediction.
  • Neurophet AQUA analyzes brain atrophy and white matter hyperintensities (WMH) found in brain MRI of most Alzheimer's disease patients.
  • Neurophet SCALE PET provides quantitative regional amyloid beta deposition, known as the causative agent of Alzheimer's disease, using PET images.
  • Neurophet plans to launch total solution for Alzheimer's disease treatment including ARIA analysis, since Neurophet has the technology to analyze ARIA.

VUNO Secures FDA 510(k) Clearance for VUNO Med®-DeepBrain®

Retrieved on: 
Monday, October 23, 2023

SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.

Key Points: 
  • SEOUL, South Korea, Oct. 23, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company has received 510(k) clearance from the Food and Drug Administration (FDA) for its AI-powered brain quantification device, VUNO Med®-DeepBrain®.
  • VUNO Med®-DeepBrain® is intended to automate the current manual process of identifying, labeling, and quantifying segmentable brain structures from MRI images.
  • With the FDA clearance in hand, VUNO intends to bolster its sales and marketing efforts targeting US medical institutions.
  • VUNO has previously explored the potential for early diagnosis of Alzheimer's disease with information provided by VUNO Med®-DeepBrain® through clinical research.

Myelofibrosis Market Size and Trend Report 2023-2031: Projected $2.89 Billion Market by 2031 - MF Pipeline is Robust, with Plenty of Room for New Market Entrants - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 3, 2023

The "Myelofibrosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myelofibrosis Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for myelofibrosis (MF).
  • In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales.
  • The most promising candidates in Phase III and Phase IIb development are profiled
    Analysis of the current and future market competition in the global myelofibrosis therapeutics market.

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2023: Featuring Iovance, Candel Therapeutics & Replimune - ResearchAndMarkets.com

Retrieved on: 
Friday, April 7, 2023

The report also analyzes the clinical and commercial landscapes of NSCLC, with pricing assumptions based on currently marketed products by class of cell & gene therapies, accompanied by a transparent forecast methodology.

Key Points: 
  • The report also analyzes the clinical and commercial landscapes of NSCLC, with pricing assumptions based on currently marketed products by class of cell & gene therapies, accompanied by a transparent forecast methodology.
  • Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.
  • Cell & gene therapies (CGTs) constitute a very small proportion of the overall NSCLC pipeline and will face a high level of competition.
  • Our indication specific forecast models answer questions such as:
    What is the target patient pool for cell & gene therapies in each cancer indication?

Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023

Retrieved on: 
Thursday, March 2, 2023

Neurophet SCALE PET is an AI-based PET image analysis software that quantifies PET tracer bindings automatically.

Key Points: 
  • Neurophet SCALE PET is an AI-based PET image analysis software that quantifies PET tracer bindings automatically.
  • Neurophet is carrying out the ATNV Project, a national research project using the flagship products Neurophet AQUA and Neurophet SCALE PET funded by Korea dementia research center.
  • Monitoring and management of ARIA are essential for prescribing anti-amyloid antibody drugs, and it seems to be possible to analyze ARIA through Neurophet's ATNV project technology.
  • He added, "The vascular neuropathology quantification technology for analyzing WMH and ARIA-H could also be used to diagnose multiple sclerosis, and the technology is being advanced."

Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 16, 2023

The "Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M).
  • Additionally, the report evaluates indication-specific unmet needs, competitive assessment, and identifies key future players in the cell therapy market.
  • The presence of marketed and pipeline CAR-T cell therapies in the 3L+ setting addresses the unmet need of providing therapeutic options for heavily pre-treated patients

Acute Lymphocytic Leukemia (ALL) Global Market Report 2023: Featuring Novartis, Gilead, Autolus Therapeutics, Gamida Cell & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 15, 2023

This report also contains a sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 major markets (15MM).

Key Points: 
  • This report also contains a sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 major markets (15MM).
  • Additionally, the report evaluates indication-specific unmet needs and competitive assessments and identifies key future players in the cell therapy market.
  • Pipeline CAR-Ts will likely require a novel target, increased efficacy, lower price, or simplified manufacture to penetrate the crowded CAR-T market.
  • Launch of pipeline CAR-Ts and "other" cell therapies will also contribute to this growth, but to a lesser extent.

World Mode Malaysia: A Leading Japanese Fashion Retail Consultancy Has Arrived in Malaysia

Retrieved on: 
Friday, February 3, 2023

World Mode Holdings Group (WMH Group) sets to elevate the beauty and fashion retail industry here with the establishment of World Mode Malaysia (WM Malaysia) and starts to offer services in February 2023.

Key Points: 
  • World Mode Holdings Group (WMH Group) sets to elevate the beauty and fashion retail industry here with the establishment of World Mode Malaysia (WM Malaysia) and starts to offer services in February 2023.
  • WM Malaysia is part of WMH Group’s expansion plans into several other new markets, including Thailand, Indonesia, and Vietnam.
  • View the full release here: https://www.businesswire.com/news/home/20230122005045/en/
    Service of WM Malaysia (Graphic: Business Wire)
    WMH Group is Japan’s leading fashion and beauty retail consultancy with a proven record of enhancing its client’s brand presence in an ever-changing retail landscape, owning the largest market share of recruiting sales professionals for Japan’s fashion and beauty industry.
  • Aiming to support clients’ business expansion and branding to keep up with retail digitalization, WMH Malaysia will launch e-learning platform and advanced retail technology.

Chronic Lymphocytic Leukemia (CLL) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Retrieved on: 
Monday, February 20, 2023

These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.

Key Points: 
  • These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.
  • The report also analyzes the clinical and commercial landscapes of CLL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.
  • Additionally, the report evaluates indication-specific unmet needs and competitive assessments and identifies key future players in the cell therapy market.
  • Cell therapy is a promising modality for treating CLL and can provide the most value by demonstrating long-term disease control in high-risk and young patients.

Neurophet, to participate in the Radiological Society of North America RSNA 2022

Retrieved on: 
Friday, November 25, 2022

SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the 25th that Neurophet would participate in the Radiological Society of North America 2022 (RSNA 2022). At this conference, Neurophet will showcase several AI analysis solutions for brain imaging, including Neurophet SCALE PET, which has received the U.S. Food and Drug Administration (FDA) 510(k) clearance.

Key Points: 
  • SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the 25th that Neurophet would participate in the Radiological Society of North America 2022 (RSNA 2022).
  • Neurophet plans product-specific demonstrations and product introductions at the booth so that on-site participants can experience Neurophet's solutions.
  • At this conference, Neurophet will share research, both independently and jointly done, related to brain image analysis through digital posters and oral sessions.
  • Chicago, USA hosts the RSNA annually, which starts this year on the 27th (local time) and runs until the 1st of the following month.